Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial

2015120 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet Oncology

Volume 16, Issue 15, pp. 1493-1505

Field-Weighted Citation Impact: 9.70